These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 19275964)
41. Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors. Wang L; Zhang B; Ji J; Li B; Yan J; Zhang W; Wu Y; Wang X Eur J Med Chem; 2009 Aug; 44(8):3318-22. PubMed ID: 19375196 [TBL] [Abstract][Full Text] [Related]
42. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors. Park WS; Kang SK; Jun MA; Shin MS; Kim KY; Rhee SD; Bae MA; Kim MS; Kim KR; Kang NS; Yoo SE; Lee JO; Song DH; Silinski P; Schneider SE; Ahn JH; Kim SS Bioorg Med Chem Lett; 2011 Mar; 21(5):1366-70. PubMed ID: 21306895 [TBL] [Abstract][Full Text] [Related]
43. From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV. Nordhoff S; López-Canet M; Hoffmann-Enger B; Bulat S; Cerezo-Gálvez S; Hill O; Rosenbaum C; Rummey C; Thiemann M; Matassa VG; Edwards PJ; Feurer A Bioorg Med Chem Lett; 2009 Aug; 19(16):4818-23. PubMed ID: 19576767 [TBL] [Abstract][Full Text] [Related]
44. K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent. Takasaki K; Iwase M; Nakajima T; Ueno K; Nomoto Y; Nakanishi S; Higo K Eur J Pharmacol; 2004 Feb; 486(3):335-42. PubMed ID: 14985056 [TBL] [Abstract][Full Text] [Related]
45. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. Xie H; Zeng L; Zeng S; Lu X; Zhang G; Zhao X; Cheng N; Tu Z; Li Z; Xu H; Yang L; Zhang X; Huang M; Zhao J; Hu W Eur J Med Chem; 2012 Jun; 52():205-12. PubMed ID: 22475866 [TBL] [Abstract][Full Text] [Related]
46. Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors. Edmondson SD; Wei L; Xu J; Shang J; Xu S; Pang J; Chaudhary A; Dean DC; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Scapin G; Wu JK; Beconi MG; Thornberry NA; Weber AE Bioorg Med Chem Lett; 2008 Apr; 18(7):2409-13. PubMed ID: 18331795 [TBL] [Abstract][Full Text] [Related]
47. 1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes. Andrews KM; Beebe DA; Benbow JW; Boyer DA; Doran SD; Hui Y; Liu S; McPherson RK; Neagu C; Parker JC; Piotrowski DW; Schneider SR; Treadway JL; VanVolkenberg MA; Zembrowski WJ Bioorg Med Chem Lett; 2011 Mar; 21(6):1810-4. PubMed ID: 21324688 [TBL] [Abstract][Full Text] [Related]
48. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. Zhang Z; Wallace MB; Feng J; Stafford JA; Skene RJ; Shi L; Lee B; Aertgeerts K; Jennings A; Xu R; Kassel DB; Kaldor SW; Navre M; Webb DR; Gwaltney SL J Med Chem; 2011 Jan; 54(2):510-24. PubMed ID: 21186796 [TBL] [Abstract][Full Text] [Related]
49. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors. Zhang L; Su M; Li J; Ji X; Wang J; Li Z; Li J; Liu H Chem Biol Drug Des; 2013 Feb; 81(2):198-207. PubMed ID: 22994702 [TBL] [Abstract][Full Text] [Related]
50. Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor. Finlay HJ; Lloyd J; Vaccaro W; Kover A; Yan L; Bhave G; Prol J; Huynh T; Bhandaru R; Caringal Y; DiMarco J; Gan J; Harper T; Huang C; Conder ML; Sun H; Levesque P; Blanar M; Atwal K; Wexler R J Med Chem; 2012 Apr; 55(7):3036-48. PubMed ID: 22409629 [TBL] [Abstract][Full Text] [Related]
51. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine). Hu SX; Soll R; Yee S; Lohse DL; Kousba A; Zeng B; Yu X; McPherson A; Renick J; Cao J; Tabak A; Hood J; Doukas J; Noronha G; Martin M Drug Metab Dispos; 2007 Jun; 35(6):929-36. PubMed ID: 17371799 [TBL] [Abstract][Full Text] [Related]
52. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. Biftu T; Sinha-Roy R; Chen P; Qian X; Feng D; Kuethe JT; Scapin G; Gao YD; Yan Y; Krueger D; Bak A; Eiermann G; He J; Cox J; Hicks J; Lyons K; He H; Salituro G; Tong S; Patel S; Doss G; Petrov A; Wu J; Xu SS; Sewall C; Zhang X; Zhang B; Thornberry NA; Weber AE J Med Chem; 2014 Apr; 57(8):3205-12. PubMed ID: 24660890 [TBL] [Abstract][Full Text] [Related]
53. Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues. Diez-Torrubia A; Balzarini J; Andrei G; Snoeck R; De Meester I; Camarasa MJ; Velázquez S J Med Chem; 2011 Mar; 54(6):1927-42. PubMed ID: 21332170 [TBL] [Abstract][Full Text] [Related]
54. DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity. Yeh KC; Yeh TK; Huang CY; Hu CB; Wang MH; Huang YW; Chou LH; Ho HH; Song JS; Hsu T; Jiaang WT; Chao YS; Chen CT Life Sci; 2021 Aug; 278():119574. PubMed ID: 33961850 [TBL] [Abstract][Full Text] [Related]
55. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors. Sharma M; Gupta M; Singh D; Kumar M; Kaur P Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413 [TBL] [Abstract][Full Text] [Related]
56. Synthesis and evaluation of thiouracil derivatives as dipeptidyl peptidase IV inhibitors. Sharma M; Singh D; Gupta M Chem Biol Drug Des; 2013 Feb; 81(2):257-64. PubMed ID: 23039850 [TBL] [Abstract][Full Text] [Related]
57. Dipeptidyl peptidase-4 inhibitor with β-amino amide scaffold: synthesis, SAR and biological evaluation. Kim HJ; Kwak WY; Min JP; Sung SY; Kim HD; Kim MK; Kim HS; Park KJ; Son MH; Kim SH; Lee BJ Bioorg Med Chem Lett; 2012 Sep; 22(17):5545-9. PubMed ID: 22850208 [TBL] [Abstract][Full Text] [Related]
58. Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors. Ji X; Su M; Wang J; Deng G; Deng S; Li Z; Tang C; Li J; Li J; Zhao L; Jiang H; Liu H Eur J Med Chem; 2014 Mar; 75():111-22. PubMed ID: 24531224 [TBL] [Abstract][Full Text] [Related]
59. Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors. Zhu Y; Xia S; Zhu M; Yi W; Cheng J; Song G; Li Z; Lu P Eur J Med Chem; 2010 Nov; 45(11):4953-62. PubMed ID: 20800322 [TBL] [Abstract][Full Text] [Related]
60. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes. Brigance RP; Meng W; Fura A; Harrity T; Wang A; Zahler R; Kirby MS; Hamann LG Bioorg Med Chem Lett; 2010 Aug; 20(15):4395-8. PubMed ID: 20598534 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]